Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

Ebolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a f...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-02, Vol.6 (1), p.21674-21674, Article 21674
Main Authors: Marzi, Andrea, Murphy, Aisling A., Feldmann, Friederike, Parkins, Christopher J., Haddock, Elaine, Hanley, Patrick W., Emery, Matthew J., Engelmann, Flora, Messaoudi, Ilhem, Feldmann, Heinz, Jarvis, Michael A.
Format: Article
Language:English
Subjects:
13/106
13/31
45/29
45/77
631/250/590
631/326/590/1867
82/1
Animals
Antibodies
Antibodies, Viral - blood
Cell-mediated immunity
Cytomegalovirus
Cytomegalovirus - genetics
Disease Models, Animal
Drug Carriers
Ebola Vaccines - administration & dosage
Ebola Vaccines - genetics
Ebola Vaccines - immunology
Ebola virus
Female
Health problems
Hemorrhagic Fever, Ebola - prevention & control
Humanities and Social Sciences
Lethality
Localization
Lymphocytes T
Macaca mulatta
Male
multidisciplinary
Outbreaks
Public health
Science
Science (multidisciplinary)
Survival Analysis
Vaccines
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ebolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep21674